Infant Formula Protein Hydrolysates Market Size - By Product Type, By Application, By End Use Industry, Growth Forecast, 2025 - 2034

Infant Formula Protein Hydrolysates Market Size

The global infant formula protein hydrolysates market size was estimated at USD 2.1 billion in 2024. The market is expected to grow from USD 2.3 billion in 2025 to USD 5.1 billion in 2034, at a CAGR of 9% according to latest report published by Global Market Insights Inc.

• This continuous increase in recognition is indicative of the growing popularity of hydrolyzed protein formulas for specified nutrition in infants with special diets and allergies.
   
• The market's growth, in fact, stems from the uprising cases of food allergies and other intolerances to infants. According to the American Academy of Pediatrics, about 3% of infants have cow milk protein allergy. Additionally, 0.51 % of infants in the U.S. suffer from food protein-induced enterocolitis syndrome (FPIES), although it is known that 60-90% of these cases resolve by 3 years of age. Such clinical situations warrant specific nutritional interventions and engender an enduring demand for hydrolyzed protein formulations.
   
• The reviews have yielded growth in this market over the years and the assessment shows that the market size will grow. Such patterns of growth reflect both organic market expansion and pioneering product formulations to meet the changing consumer wants and clinically related needs.
   
• By and large, premium pricing strategies for advanced formulations underpin the value of the market, the most expensive among infant formulas being hydrolyzed protein. Cost justification for the difference comes from sophisticated processing technologies required for protein hydrolysis, extensive clinical validation, and adherence to regulatory requirements across jurisdictions. Modern hydrolysis technologies, namely enzymatic and thermal methods, will produce more easily digestible and less allergenic products.
   

Infant Formula Protein Hydrolysates Market Trends

• Increasing Demand for Hypoallergenic and Specialized Formulations- Principal reason responsible for market growth is increasing demand for hypoallergenic and specialized formulations aimed at salt and allergic babies. The prevalence of food allergies among children aged 0-17 years in the U.S. is 5.8%, increasing with age, where 4.4% prevalence is observed in 0-5-year-old children and 7.1% in 12-17-year-old children. Substantial increase in allergic cases is thus keeping the demand for specialized nutritional solutions consistent. Cow milk protein allergy is the most significant factor among these demands, affecting up to 3% of infants and requiring immediate diet modifications.
   
• The American Academy of Pediatrics recommends that most formula-fed infants with CMPA can tolerate extensively hydrolyzed formulas, hence making such products first-line therapeutic interventions for these cases. Clinical effectiveness of hydrolyzed formulas in managing allergy disorders is encouraging healthcare providers to recommend their use and parents to accept them.
   
• Growing Preference for Organic and Plant-Based Protein Hydrolysates- The trend is most prominently driven by health-conscious parents looking for natural and sustainable nutritional solutions for their infants towards organic and plant-based protein hydrolysates. The trend which, in a larger view, follows the consumer's general movement towards organic food products and environmental sustainability concerns affecting purchasing decisions.
   
• Inorganically, the segment of the hydrolyzed protein market should be witnessing stronger growth momentum weighed against other product positioning segments also. Parents are willing to pay a premium for organic formulations where products do not use any synthetic additives, pesticides, and genetically modified ingredients.
   
• Technological Advancements in Hydrolysis Processes- Technological innovation in protein hydrolysis is revolutionizing the efficacy and digestibility of formula, creating products with better nutritional profiles and therapeutic benefits. Advanced enzymatic and thermal processing methods are able to remove allergenic epitopes while maintaining essential amino acid composition.
   
• Today's state-of-the art hydrolysis technique provides tighter control over the molecular weight distribution such that extensively hydrolyzed formulas achieve peptide sizes and weights below 3 kDa and partially hydrolyzed formulas have molecular weight ranging from 5-10 kDa. This specification ensures an optimal compromise between lowering allergenicity and maintaining nutritional function. Whey protein hydrolysates have better digestibility and rapid emptying from the stomach than intact protein, thereby increasing amino acids absorption and making nutrients bioavailable. These technological advances are underpinned by extensive research demonstrating improved protein utilization and favorable growth outcomes in clinical studies.
   

Infant Formula Protein Hydrolysates Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The product type segmentation shows different performance trends and growth paths in the hydrolyzed protein formulations. Extensively Hydrolyzed Formula (eHF) commands a huge Infant formula protein hydrolysates market share of about 45% in 2024, reflecting the extent of their clinical application and established efficacy in managing cow milk protein allergy. These formulations undergo extensive breakdown of proteins to create specific peptides with molecular weights below 3 kDa, which significantly attenuate the allergic potential but meet nutritional requirements.
 

Extensively hydrolyzed formulas are the first-line treatments for infants with CMPA, as most of such formula-fed infants are able to tolerate eHF products, as recommended by the American Academy of Pediatrics. The constant demand growth and wide increase in market shares can be attributed to clinical validity and clinician confidence in these formulations. The manufacturing processes for eHF involve highly intricate enzymatic hydrolysis techniques requiring heavy investment in technology and skilled personnel, thus preventing new entrants from entering the market and bringing benefits to established manufacturers.
 

Amino Acid-Based Formula (AAF) comprises 25% of the Infant formula protein hydrolysates market share in 2024 for infants presenting with severe allergies. These formulations are entirely based on the supply of each of the individual amino acids, hence eliminating all allergenic potential while supporting ideal growth and development. At the same time, AAF products priced high because of the specialty in the case they deal with, and limited patient population have contributed to market value disproportionally, even though they have a smaller market share in volume terms.
 

Learn more about the key segments shaping this market

Download Free PDF

The application segmentation clearly illustrates the clinical focus of the hydrolyzed protein market, with food allergy management segment accounting for 55% of Infant formula protein hydrolysates market share in 2024. This dominant segment illustrates the therapeutic use of hydrolyzed formulas in treating cases of cow milk protein allergy, food protein-induced enterocolitis syndrome, and other food-associated allergic conditions. The hydrolyzed proteins are clinically effective in reducing allergic attacks while providing adequate nutrition, which continues to steer pressures from healthcare providers recommending hydrolyzed formulas and therefore sustaining the demand growth.
 

Food allergy management applications benefit from strong clinical backing and established treatment guidelines, making hydrolyzed infant formulas the usual standard of care. Clinical validation supporting the use of extensively hydrolyzed formulas for managing CMPA from the American Academy of Pediatrics enhances the market uptake. This application segment sees stable growth patterns, bolstered by the constant prevalence of allergies and the confidence within the healthcare providers regarding the therapeutic outcomes.
 

Gastrointestinal disorders constitute 20% of the Infant formula protein hydrolysates market share of applications in 2024, addressing conditions such as malabsorption syndromes, inflammatory bowel conditions, and immaturity of digestive systems, which benefit from pre-digested protein sources. Hydrolysis of proteins enhances the digestibility and speed of gastric emptying, which minimizes gastrointestinal stress while providing adequate nutrition. With greater understanding of infant gastrointestinal health and improvement in diagnostic capacity, it stands to reason that this application segment has lots of growth potential.
 

Growth & Nutritional Support makes up 15% market share of applications in 2024 and is aimed at infants affected by failure to thrive, risks from premature birth, or any conditions requiring more aggressive nutritional support. Hydrolyzed proteins have improved bioavailability and amino-acid absorption is beneficial to optimal growth outcomes of infants in at-risk groups. With the increased survival rates of preterm infants and increasing awareness on their special nutritional needs, this application is benefitting.
 

Looking for region specific data?

Download Free PDF

• The U.S. infant formula protein hydrolysates market reached USD 589.3 million in 2024 and estimated to grow to almost USD 1.2 billion by 2034. Food allergy cases have risen and are growing continuously, according to CDC data-they affect 5.8% of children aged 0-17, flaring up the market growth in North America. Recommendations made by the American Academy of Pediatrics and insurance coverage provided for medically necessary formulations reinforce strong acceptance among healthcare providers for using hydrolyzed formulas in this region. Acceptance of premium pricing and willingness to spend on specialized nutrition create market conditions conducive to continued growth.
   
• Europe holds 30% of global market share in 2024, being a region with very strict regulatory requirements that encourage the addition of premium products and consumer confidence about specialized formulations. The European Union has ensured comprehensive legislation for such stressing ensures top quality of its products and easy access by approved ones to the market. Strong demand for organic and premium formulations are seen in some of the European powerhouse markets, such as Germany, the UK, and France, aided through health-conscious consumer demand and a sound healthcare system.
   
• Market dynamics in Europe embody cultural predisposition towards natural and organic products, hence driving the demand for premium hydrolyzed formulations meeting strict quality standards. Considering that the region stresses preventive and early health actions with regards to infant health conditions, sustained growth of the market is assured. Regulatory harmonization across EU member states facilitates manufacturers' efficient market access and distribution of products.
   
• Asia Pacific is considered to exhibit the highest potential for expansion due to its enormous population base, increasing disposable income, and growing awareness about specialized infant nutrition. The region is comprised of these major markets: China, India, Japan, and South Korea, having unique characteristics and growth drivers. Rising birth rates, urbanization, and increasing female participation in the workforce are creating favorable demographic trends for the growth of the formula market.
   
• Latin America accounted for the 10% of the market share in 2024 in the global market driven mainly by growth opportunities in Brazil and Argentina. There has been growing interest in learning about infant nutrition within this region, along with the increased popularity of specialized formulations. In improving healthcare access and economic growth, there will be more opportunities for market expansion; however, price sensitivity continues to dominate as a marketing consideration for product positioning and penetration.
   
• The Middle East and Africa show fine potential for future growth in the light of economic growth, bettering healthcare infrastructure, and a rising awareness of infant nutrition. The young population coupled with increasing disposable income creates the favorable growth conditions for market expansion. Government initiatives supporting maternal and infant health go hand in hand with increased access to healthcare, hence amplifying demand for specialized nutritional products including hydrolyzed protein formulations.
   

Infant Formula Protein Hydrolysates Market Share

The infant formula protein hydrolysates industry is characterized by moderate concentration and an overall presence of leading players who have strengthened their positions in the market through technological innovation, clinical validation, and comprehensive product portfolios. With 61% of the market accounted for by the top five companies Abbott Laboratories, Reckitt Benckiser (Mead Johnson), Nestlé S.A., Danone S.A., Arla Foods Ingredients, Morinaga Milk Industry, it is evident that these companies control a considerable market share while allowing some playroom for niche players and emerging competitors to set up specialized positions.
 

Abbott Laboratories occupies a substantial market position through the Similac brand portfolio, which contains varieties of extensively hydrolyzed and amino acid-based preparations to manage food allergies in infants. Abbott's part of the market is largely a product of its robust clinical validations, relationships with health professionals, and comprehensive product scope for various therapeutic needs. Thus, patent continuing support for the company from research and development and its global distribution network should also promote continuous presence in the market.
 

With the Nutramigen brand-under Mead Johnson-offering extensively hydrolyzed formula identified as one of the best therapeutic approaches to cow milk protein allergy management, Reckitt Benckiser still commands substantial market share. In addition to these features, the strong name recognition and clinical efficacy authentication enjoyed by such brand name along with endorsements from doctors add strength to the market position of the company. Mead Johnson has developed an exclusive focus on specialized nutrition and therapeutic formulations based on competitive advantages for price segments in the premium market.
 

Infant Formula Protein Hydrolysates Market Companies

Major players operating in the infant formula protein hydrolysates industry are:
 

• Abbott Laboratories
• Reckitt Benckiser
• Nestlé
• Danone
• Arla Foods Ingredients
• Morinaga Milk Industry
• Biostime International
• Bellamy's Organic
• HiPP
• ByHeart
• Else Nutrition
• Perrigo Company
• Kendamil
  
   
• Abbott Laboratories
  • Abbott Laboratories thus becomes the world leader in infant nutrition, leveraging the complete expertise in specialized formulas for the management of food allergies and gastrointestinal conditions. Under its Similac brand portfolio, the company has newly introduced extensively hydrolyzed and amino acid-based formulations that will be used as therapeutic interventions for infants suffering from cow-milk-protein allergy and other food sensitivities. Decades of clinical research, regulatory expertise, and healthcare provider relationships-legitimizing product adoption and penetration into the market-where Abbott's market position now stands.
     
• Reckitt Benckiser
  • Mead Johnson, the infant nutrition specialist business unit of Reckitt Benckiser, established its presence as a therapeutic nutrition company. One of the most well-recognized extensively hydrolyzed formulas in the world - Nutramigen by Mead Johnson - is based on a good deal of clinical validation and endorsement for use by health providers. Mead Johnson's market positioning is primarily clinical excellence, health provider education, and premiumization in the therapeutic sections.
     
• Nestlé S.A
  • Nestlé S.A.'s dominance in the food and beverage sector enables it to have a formidable leverage over all infant nutrition markets in the world. The infant formula collection of this company offers prescribed uses of specialized formulations and has been kept with robust research capabilities to reach into the wider distribution channels. Nestlé's market approach has been backed by scientific innovations, quality guarantee, and holistic product portfolios that answer the broad spectrum of requirements from diverse consumers.
     
• Danone S.A.
  • Danone S.A. specialized use-specific nutrition through its therapeutic nutrition division, with premium therapy making the top-formulations against particular medical conditions and consumer preferences. Under its strategy, organic and natural formulations and evidence from clinical studies coupled with those from healthcare providers will ensure acceptance of the products in the market. Danone's commitment to environmental sustainability and responsibility echoes the changing trends among consumers and regulatory frameworks.
     
• Arla Foods
  • Arla Foods Ingredients specializes in the market for hydrolyzed protein by dairy protein processing and ingredient innovations. Its business model does not focus on direct sales to consumers but on supplying high-quality protein to formula manufacturers. The support with which Arla's technical capabilities in protein hydrolysis, functional ingredient development, and quality assurance continue to fuel innovation and growth in the broader industry.
     
• Morinaga Milk
  • Morinaga Milk Industry has a special stronghold in the Asian markets, particularly strong in Japan and gradually building up across the Asia Pacific regions. Exceptionally qualified in dairy processing, fermentation technologies, and specialized nutrition, the company enjoys competitive advantages in regional markets characterized by specific cultural preferences and regulatory requirements.
     

Infant Formula Protein Hydrolysates Industry News

• In November 2024, Abbott Laboratories announced an expansion of the manufacturing facility in Ireland to enhance the capacity for the production of specialty infant formulas, including extensively hydrolyzed formulations. This USD 200 million investment intends to ensure an international and European supply chain survivability while fulfilling ever-growing global requirements for therapeutic infant nutrition products.
   
• In July 2024, Arla Foods Ingredients secured US Food & Drug Administration permission for the use of whey protein hydrolysates that support allergy management and gut comfort in infant formula. The FDA agreed that four ingredients in the company’s product known as Peptigen and Lacprodan ranges meet the definition of peptones in the US Code of Federal Regulations
   
• In October 2024, FrieslandCampina Ingredients announced that its Hyvital Whey HA 300, a protein hydrolysate designed for use in infant and follow-on formulas, has now been authorized for use throughout the entire European Union.
   

The infant formula protein hydrolysates market research report includes in-depth coverage of the industry, with estimates & forecast in terms of revenue (USD Billion) and volume (Kilo Tons) from 2021 to 2034, for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Extensively hydrolyzed formula (eHF)
  • Casein-based eHF
  • Whey-based eHF
• Partially hydrolyzed formula (pHF)
  • Casein-based pHF
  • Whey-based pHF
• Amino acid-based formula (AAF)
• Rice protein hydrolysate formula
• Others

Market, By Application

• Food allergy management
  • Cow's milk protein allergy (CMPA)
  • Multiple food protein intolerance (MFPI)
  • Food protein-induced enterocolitis syndrome (FPIES)
  • Eosinophilic gastrointestinal disorders
• Gastrointestinal disorders
  • Functional gastrointestinal disorders
  • Malabsorption syndromes
  • Inflammatory bowel conditions
  • Structural gastrointestinal disorders
• Growth & nutritional support
  • Failure to thrive
  • Metabolic disorders
  • Pancreatic insufficiency
• Critical care & hospital applications
  • Neonatal intensive care unit (NICU)
  • Pediatric intensive care unit (PICU)
  • Emergency department applications
• Others
  • Immunodeficiency disorders
  • Neurological conditions
  • Genetic syndromes
• Oncological applications

Market, By End Use Industry

• Hospital & healthcare systems
• Government & public programs
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa